Organoid Clinical Trial against CoVID-19, page-93

Bottom line is that there is ' Room ' in this Market for many varying strengths and drugs for the successful management , treatment , and ongoing therapy which may arise from the effects of this highly ' infectious ' virus in COVID-19. And the Market in these stocks knows this. It's just they are looking for anything they can get started and use right NOW.

There will be room for MPL no worries about that - just as there are so many anti bacterial and Antibiotic' s and levels of strength in that Pharmaceutical Category. With the inhibitor's market , there will also be varying levels of strengths and dosages required for different levels of viral severity , Age , immune system levels , and of course other preexisting conditions. I don't reckon it will ever be a case of one size or treatment fits ALL.

So no need to get all stressed every time we hear an announcement from a ' competing ' Biotech that they are onto something. Because , there are a lot of People , Talent , and Money being spent on this .....from virtually everywhere. And I believe ZINC was also mentioned alongside and in tandem with a dosage of hydroxychloroquine originally , and we all know where that has more or less come to.